Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

Leukemia. 2015 Mar;29(3):741-4. doi: 10.1038/leu.2014.306. Epub 2014 Nov 11.

Authors

A Pardanani¹, R A Abdelrahman¹, C Finke¹, T T Lasho¹, K H Begna¹, A Al-Kali¹, W J Hogan¹, M R Litzow¹, C A Hanson², R P Ketterling³, A Tefferi¹

Affiliations

¹ Division of Hematology and Department of Medicine, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
³ Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Benzamides / therapeutic use*
Calreticulin / genetics*
Drug Administration Schedule
Female
Gene Expression
Genetic Markers
Humans
Janus Kinase 1 / genetics
Janus Kinase 2 / genetics
Male
Middle Aged
Mutation
Primary Myelofibrosis / drug therapy*
Primary Myelofibrosis / genetics*
Primary Myelofibrosis / mortality
Primary Myelofibrosis / pathology
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Receptors, Thrombopoietin / genetics
Repressor Proteins / genetics*
Survival Analysis

Substances

ASXL1 protein, human
Benzamides
CALR protein, human
Calreticulin
Genetic Markers
Protein Kinase Inhibitors
Pyrimidines
Receptors, Thrombopoietin
Repressor Proteins
MPL protein, human
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
JAK2 protein, human
Janus Kinase 1
Janus Kinase 2